Fresenius Medical Care Deutschland Gmbh

Fresenius Ag

Fresenius Medical Deutschland Gmbh

Pss Polymer Standards Service Gmbh

Jutta Passlick-Deetjen

Klaus Sommermeyer

Rainer Fislage

Ulrich Tschulena

Annika Hörberg

Sonja Steppan

Wolfgang Hofmann

Georg Topp

Abelardo Isaac Aguilera Peralta

Manuel Lopez-Cabrera

Rafael Selgas Gutierrez

Friedrich Schulze

Thomas P Schaub

Anja Kuhn

Peter Mirjam

Yolanda Almaden Pena

Pedro Aljama Garcia

Mariano Rodriguez Portillo

Julio Manuel Martinez-Moreno

Juan Miguel Diaz Tocados

Maria Encarnacion Rodriguez Ortiz

Addy Rosa Montes De Oca Gonzalez

Carmen Herencia Bellido

Kirsten Oleschko

Hans Peter Leinenbach

Günter Reinhold

Janine BÜCHEL

Manuel LÓPEZ-Cabrera

Kristina Gundlach

The present invention relates to a solution for peritoneal dialysis consisting of one or more separate solutions. A treatment free of side-effects with a simultaneous lowering of blood pressure can be achieved in that the solution contains sodium ions in a concentration in the region from 121 to 129 mmol/l, preferably at 125 mmol/l. The invention furthermore relates to a double-chambered pouch having a peritoneal dialysis solution consisting of two separate solutions which consists of a plastic pouch in which a first chamber with the first separate solution and a second chamber with the second separate solution are arranged adjacent to one another, with both chambers being separated from one another by a weld seam dimensioned such that it opens on pressure onto one of the chambers filled with liquid so that the content of the two chambers can be mixed with one another.

Peritoneal dialysis solution

The present invention relates to pharmaceutical compositions containing steviol glycoside and or steviol glycoside derivatives as well as to their use as osmotics in particular for use in the treatment of chronic renal failure by dialysis.

Pharmaceutical compositions containing steviosides

The invention relates to a device and a method for depletion of hepcidin from blood for treatment of iron deficiency, in particular in anemic patients suffering from chronic renal failure, with the goal of increasing the availability of iron in the body and thus improving the treatment of the anemia. The hepcidin adsorbent comprises a matrix and a hepcidin-binding ligand covalently bonded to the matrix with an affinity having a dissociation constant KD of less than 200 nM.

Adsorbents for the adsorption of hepcidin

The present invention relates to dialysis solutions for peritoneal dialysis, containing hydroxyethyl starch as the osmotically-active substance, electrolytes and, optionally, conventional additives, where the hydroxyethyl starch has a molecular weight Mw in the range from 10,000 to 150,000, a substitution MS in the range from 0.10 to 0.40, a substitution DS in the range from 0.09 to 0.35 and a substitution ratio C2/C6&gE;8. With this peritoneal dialysis solution it is possible, with an outstanding ultrafiltration, to maintain a longer dwell time, for example the dialysis solution can be utilized for a period of 12 hours in the CAPD without replacement. In addition, the inventive dialysis solution is also particularly advantageous for patients with residual kidney function. The resorption of the osmotically active substance is clearly diminished and even after a dwell time of 12 hours it amounts to a maximum of 60-70%.

Dialysis solution for peritoneal dialysis

Growing community of inventors

Giessen, Germany

Jutta Passlick-Deetjen